Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, Aso Y. Jojima T, et al. Among authors: iijima t. Int J Cardiol. 2021 May 15;331:243-248. doi: 10.1016/j.ijcard.2021.01.063. Epub 2021 Feb 5. Int J Cardiol. 2021. PMID: 33556413 Clinical Trial.
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.
Sagara M, Iijima T, Kase M, Kato K, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Sagara M, et al. Among authors: iijima t. J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 6. J Diabetes Complications. 2021. PMID: 33602617
Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Iijima T, Hosonuma S, Kurai H, Kajitani H, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Iijima T, et al. Int J Clin Pract. 2021 Nov;75(11):e14732. doi: 10.1111/ijcp.14732. Epub 2021 Aug 19. Int J Clin Pract. 2021. PMID: 34388297
Effects of treatment with methimazole on circulating CD4+ and CD8+ T cells positive for programed cell death protein-1 and on subsets of CD4+ T cells in untreated hyperthyroid patients with Graves' disease.
Hirao N, Iijima T, Tanuma D, Ohira E, Kurai H, Shinzawa T, Kase M, Sakurai S, Tomaru T, Jojima T, Usui I, Aso Y. Hirao N, et al. Among authors: iijima t. Clin Endocrinol (Oxf). 2022 Dec;97(6):841-848. doi: 10.1111/cen.14788. Epub 2022 Jun 17. Clin Endocrinol (Oxf). 2022. PMID: 35692119
1,036 results